ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
ANI Pharma (ANIP) Tops Q1 EPS by 15c; Suspends FY20 Guidance
May 7, 2020 8:35 AM EDTANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.04, $0.15 better than the analyst estimate of $0.89. Revenue for the quarter came in at $49.8 million versus the consensus estimate of $50.23 million.
For the first quarter 2020, ANI reports:
Net revenues of $49.8 million versus $52.9 million in 2019GAAP net loss of $7.0 million and diluted GAAP loss per share of $0.59Adjusted non-GAAP EBITDA of $17.6 millionAdjusted non-GAAP diluted earnings per share of $1.04Arthur S. Przybyl, President and CEO,... More
